Evommune posts corporate presentation outlining Phase 2 inflammation-drug pipeline focusing on EVO756, EVO301

PUBT · 1d ago
Evommune posts corporate presentation outlining Phase 2 inflammation-drug pipeline focusing on EVO756, EVO301
  • Evommune outlined two Phase 2 programs in chronic inflammatory diseases, led by EVO756 in atopic dermatitis and migraine.
  • EVO756 Phase 2b atopic dermatitis top-line data expected in September 2026; Phase 3 planned in 1H 2027.
  • EVO756 Phase 2b migraine trial initiated in July 2026; top-line data expected in 2027.
  • EVO301 posted positive Phase 2a atopic dermatitis data in February 2026; Phase 2b planned in 2027 with subcutaneous formulation, data expected in 2028.
  • Cash and investments of about $287 million as of June 30, 2026; runway anticipated through 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.